NERVE GROWTH-FACTOR AND BROMOCRIPTINE - A SEQUENTIAL THERAPY FOR HUMAN BROMOCRIPTINE-RESISTANT PROLACTINOMAS

Nerve growth factor (NGF) administration to athymic mice with transpla nted human bromocriptine-resistant prolactinoma, results in the expres sion of dopamine D-2 receptors in the tumour and restores sensitivity to subsequent treatment with bromocriptine, which then produces normal isation of plasma prolactin and tumour regression. Sequential administ ration of NGF and bromocriptine thus may be a promising therapy for pa tients refractory to bromocriptine.